Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan + Zanzalintinib vs Cabozantinib in Advanced RCC (LITESPARK-033)
NCT07227402Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2025
- Primary completion
- Feb 2032
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 23
01
Overview
A Phase 3 trial of belzutifan, zanzalintinib in renal cell carcinoma (RCC), sponsored by Merck & Co.. Started Nov 2025; status: recruiting.
02
Drugs
belzutifanzanzalintinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07227402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227402.